Novartis Ausschüttungen und Rückkäufe

Zukünftiges Wachstum Kriterienprüfungen 5/6

Novartis ist ein dividendenzahlendes Unternehmen mit einer aktuellen Rendite von 3.48%, die durch die Erträge gut gedeckt ist.

Wichtige Informationen

3.5%

Dividendenausschüttung

3.3%

Rückkaufsrendite

Gesamte Aktionärsrendite	6.8%
Zukünftige Dividendenrendite	4.0%
Wachstum der Dividende	1.8%
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	US$3.820
Ausschüttungsquote	68%

Jüngste Updates zu Dividenden und Rückkäufen

Keine Aktualisierungen

Recent updates

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: NVSDie Dividende je Aktie war in den letzten 10 Jahren stabil.

Wachsende Dividende: NVSDie Dividendenzahlungen des Unternehmens sind in den letzten 10 Jahren gestiegen.

Dividendenrendite im Vergleich zum Markt

Novartis Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von NVS im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (NVS)	3.5%
Untere 25 % des Marktes (US)	1.4%
Markt Top 25 % (US)	4.3%
Branchendurchschnitt (Pharmaceuticals)	2.5%
Analystenprognose (NVS) (bis zu 3 Jahre)	4.0%

Bemerkenswerte Dividende: NVSDie Dividende des Unternehmens (3.48%) ist höher als die der untersten 25% der Dividendenzahler auf dem US Markt (1.4%).

Hohe Dividende: NVSDie Dividende des Unternehmens (3.48%) ist im Vergleich zu den besten 25% der Dividendenzahler auf dem Markt US (4.32%) niedrig.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Mit einer angemessenen Ausschüttungsquote (67.8%) sind die Dividendenzahlungen von NVS durch die Gewinne gedeckt.

Barausschüttung an die Aktionäre

Cashflow-Deckung: Mit einer angemessenen Ausschüttungsquote (57.2%) sind die Dividendenzahlungen von NVS durch den Cashflow gedeckt.

Novartis Ausschüttungen und Rückkäufe

Zukünftiges Wachstum Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Updates zu Dividenden und Rückkäufen

Recent updates

Novartis' Scemblix® Receives Approval from US Food and Drug Administration

Novartis Raises Earnings Guidance for the Fiscal Year 2024

What To Expect When Novartis Reports Q3 2024 Results

Novartis AG, Annual General Meeting, Mar 07, 2025

Alkem Labs Reportedly in Talks to Acquire Novartis India from Its Swiss Parent

Novartis Announces Positive Topline Results from Twice-Yearly Leqvio (Inclisiran) in the Phase III V-Mono Study

Siemens Healthineers Offers to Buy Novartis Molecular Imaging Business

Novartis Receives FDA Accelerated Approval for Fabhalta (iptacopan)

Why Novartis Deserves Your Attention After Q2 2024 Results

Novartis AG to Report Q4, 2024 Results on Jan 31, 2025

Novartis: Buy This Blue-Chip Dividend Stock On Sale Now

Novartis AG Presents Latest Phase III Fabhalta®? (iptacopan) Data in C3 Glomerulopathy (C3G)

Novartis AG (SWX:NOVN) entered into an agreement to acquire Mariana Oncology, Inc. from Atlas Venture L.P., Access Biotechnology, RA Capital Management, L.P., Deep Track Capital, LP, Forbion Capital Partners B.V. and others for $1.8 billion.

Novartis and Medicines for Malaria Venture Announce Positive Efficacy and Safety Data for A Novel Treatment for Babies

Novartis AG Revise Earnings Guidance for the Year 2024

Novartis Looks To Get Back On Track With Q1 Earnings

Novartis' Intravenous Formulation of Cosentyx Impacting Prescriber Preferences in Psoriatic Arthritis Treatment, While Pending Launch of UCB’s Bimzelx Poised to Further Disrupt the Market

Novartis Presents Results from Pre-Specified Interim Analysis of the Phase III APPLAUSE-IgAN study of Fabhalta

Novartis Fabhalta Receives Positive CHMP Opinion as First Oral Monotherapy for Adult Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Novartis AG (SWX:NOVN) acquired IFM Due, Inc. from IFM Therapeutics, LLC for approximately $840 million.

Dr. Reddy's Laboratories Denies in Race to Acquire Novartis' Stake in Novartis India

Dr Reddy's Reportedly May Join Race to Acquire Novartis' India Arm

Novartis AG Announces FDA Approves Xolair® (Omalizumab) as First and Only Medicine for Children and Adults with One or More Food Allergies

Novartis Reportedly in Lead to Acquire MorphoSys

Novartis AG Provides Earnings Guidance for the Year 2024

Novartis AG to Report Q1, 2024 Results on Apr 23, 2024

Novartis AG Presents Data from the Phase III NETTER-2 Trial

Novartis Pursuit of Cytokinetics Reportedly Cools

Novartis Reportedly in Advanced Talks to Buy Cytokinetics

Novartis AG Announces Positive Results from the Primary Analysis of ASC4FIRST

Novartis AG (SWX:NOVN) acquired SanReno Therapeutics from Pivotal bioVenture Partners China, Versant Venture Management, LLC, Samsara BioCapital LLC, Frazier Healthcare Partners managed by Frazier Management, L.L.C. and Frazier Life Sciences Management, LP.

Novartis Investigational Iptacopan Phase III Study Demonstrates Clinically Meaningful and Statistically Significant Proteinuria Reduction in Patients with C3 Glomerulopathy (C3G)

Latest Novartis Kisqali(R) Natalee Analysis Reinforces 25% Reduction in Risk of Recurrence Across Broad Population of Patients with Early Breast Cancer

Novartis Receives FDA Approval for Fabhalta (iptacopan) Offering Superior Hemoglobin Improvement in the Absence of Transfusions as the First Oral Monotherapy for Adults with PNH

Novartis AG to Report Q4, 2023 Results on Jan 31, 2024

Novartis Announces New Positive Data from the Phase III REMIX-1 and REMIX-2 Studies Investigating Remibrutinib

Novartis Announces US Food and Drug Administration Approves Cosentyx® to Treat Moderate to Severe Hidradenitis Suppurativa in Adults

Novartis Announces Positive Topline Results from the Interim Analysis of the Ongoing Pivotal Phase III ALIGN Study

New And Improved Novartis

Novartis AG Announces Impairment Charges for the Third Quarter of 2023

Novartis AG Raises Earnings Guidance for the Fiscal Year 2023

Novartis Kisqali Natalee Analysis Confirms Consistent Reduction in Risk of Recurrence Across Key Sub Groups of Patients with Early Breast Cancer

FDA Approves Novartis Cosentyx® as First Intravenous (Iv) Formulation Interleukin-17A Antagonist for Rheumatic Diseases

Novartis to Present New Oncology Data at ESMO 2023 Demonstrating Practice-Changing Innovation in Advanced Prostate and Early Breast Cancer

Novartis: Better Margin Visibility Ex-Sandoz

Novartis AG completed the Spin-Off of Sandoz Group AG (SWX:SDZ).

Bausch & Lomb Ireland completed the acquisition of ophthalmology assets of Novartis AG from Novartis AG for $2.5 billion.

Sandoz, Novartis Division, Receives European Commission Approval for Tyruko (Natalizumab), First and Only Biosimilar for Multiple Sclerosis in Europe

Novartis: Buy This Dividend Aristocrat For Consistent Income

Novartis Radioligand Therapy Lutathera® Demonstrated Statistically Significant and Clinically Meaningful Progression-Free Survival in First Line Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Stabilität und Wachstum des Zahlungsverkehrs

Dividendenrendite im Vergleich zum Markt

Gewinnausschüttung an die Aktionäre

Barausschüttung an die Aktionäre

Entdecken Sie dividendenstarke Unternehmen